ClinicalTrials.gg
CompletedNCT03965871Updated Mar 19, 2021

Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

A Phase 2 interventional study of Esketamine DPI - low dose and Esketamine DPI - medium dose in Bipolar Depression, sponsored by Celon Pharma SA. Completed at 12 sites in Poland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Celon Pharma SA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Bipolar Disorder with a site in Poland — 5 open to participants now, 5 under way, 1 of them phase 3. Bipolar Disorder · Poland.

Enrollment
21st of 22
88 · median 389
Started
2019
with 1 other
Phase 2
4 of 24
none open now
Registered
17th of 24
by date
Lead sponsor
1 of 24
Celon Pharma SA

Among the 24 studies in Bipolar Disorder with a site in Poland, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 17th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

5 of the 24 studies in Bipolar Disorder with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Bipolar Disorder with a site in Poland, or all of them as a file.
02

Study summary

The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant bipolar depression (TRBD). The study is to determine the efficacy and dose response of three Esketamine doses, compared with placebo.

Read the detailed description

This is a randomized, multiple dose, placebo-controlled, double-blind, multicentre study of Esketamine DPI, inhalation powder delivered via dry powder inhaler (DPI) in participants with TRBD. There are 3 study phases: Screening phase, a two weeks double-blind treatment phase and a 6-week follow-up phase. Participants are to be randomized in 1:1:1:1 ratio to receive placebo or one of the three doses of Esketamine DPI. Participants from each group will receive different dosing sequences, consider as a single dose, corresponding to low, medium, high Esketamine dose or placebo. Participants will undergo one cycle of treatment consisting of four doses of Esketamine DPI or placebo over 14-day period. Participants safety will be monitored throughout the study.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: female or male,
  2. Age: 18 - 65 years old, inclusive, on the day of Screening,
  3. Participant must meet , fifth edition (DSM-5) diagnostic criteria for depressive episode in Bipolar Disorder (BD) type I or II, without psychotic features, confirmed by the Mini International Neuropsychiatric Interview (MINI),
  4. Participant must have in Montgomery-Asberg Depression Rating Scale (MADRS) total score of >= 24 at Screening and predose on Day 1,
  5. Participant is treatment resistant in the current episode of depression, defined as having an inadequate response to at least 2 adequate mood stabilizing treatment regimens administered for the sufficient duration and dose and administered in the current episode of depression,
  6. Participant in the last mood stabilizing treatment regimen is to be administered at least one of the medication listed in the protocol,
  7. Participant's last mood stabilizing treatment regimen is to be without antidepressant drugs from the class: SSRI, SNRI, TCA, MAOI or NaSSA,
  8. Participant must be on stable mood stabilizing treatment regimen (listed in the protocol), remain non-responsive to it and continue the treatment from Screening to at least the duration of the double-blind treatment phase,
  9. Participant's other drugs taken as a standard treatment for bipolar disorder, but not for depressive episode treatment, are to be allowed and may be continued through the study and it's administration is up to Investigator discretion,
  10. Participant agrees to be hospitalized voluntarily for a period of 12 h before first administration and until the end of treatment phase on Day 14,
  11. Participant must be medically stable on the basis of clinical laboratory tests, physical examination, vital signs, 12-lead ,
  12. Participant agrees to blood sample collection for DNA analysis,
  13. Participant of willing to use acceptable forms of .

Exclusion criteria

Exclusion Criteria:

  1. Participant has a current diagnosis, according to MINI, of any other than BD disorder,
  2. Participant has a BD with a rapid-cycling course (≥ 4 episodes per year),
  3. Participant has in Young Mania Rating Scale (YMRS) total score of greater than 12 at Screening and every other assessment,
  4. Participant has suicidal ideation in MADRS 'suicidal thoughts' subscale score greater or equal to 2 and/or in C-SSRS score greater or equal to 4 at Screening and/or has a history of suicidal thoughts within 6 months prior to Screening and/or history of suicidal attempt within 1 year prior to Screening,
  5. Participant has a history or current signs and symptoms of (COPD), asthma, liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, hematologic, neurologic, rheumatologic or metabolic disturbances that are uncontrolled with medication change during last three months before Screening and/or that could influence the present general health condition at the Investigator's discretion,
  6. Participant has uncontrolled hypertension,
  7. Upper respiratory tract and/or chest infection and/or inflammation within 2 weeks preceding the first administration and during the treatment phase,
  8. Participant took part in other clinical trial within 90 days preceding the Screening,
  9. Known allergy or , intolerance or to Esketamine/ketamine or its derivatives and/or to any study product ,
  10. Blood drawn within 30 days prior to inclusion to the study,
  11. History of drug, alcohol, chemical, sedatives or sleeping medications abuse or dependence (except nicotine or caffeine) within 2 years prior to Screening,
  12. Lifetime abuse or dependence on ketamine or phencyclidine,
  13. Positive results from pregnancy test for female participants,
  14. Lactation in female participants,
  15. Positive drug screen (except benzodiazepines evaluation during follow-up) or alcohol breath test.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Esketamine low dose

    Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Esketamine DPI - low dose

  • Experimental
    Esketamine medium dose

    Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Esketamine DPI - medium dose

  • Experimental
    Esketamine high dose

    Participants are to receive four doses of Esketamine DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Esketamine DPI - high dose

  • Placebo comparator
    Placebo

    Participants are to receive four doses of Placebo DPI administered over 14-day period (on Day 1, 4, 8 and 11).

    Drug: Placebo DPI

Interventions

  • DrugEsketamine DPI - low dose

    Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.

  • DrugEsketamine DPI - medium dose

    Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.

  • DrugEsketamine DPI - high dose

    Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.

  • DrugPlacebo DPI

    Placebo DPI is to be administered via dry powder inhaler.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Day 14

    The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.

    Time frame: Day 1 and Day 14

Secondary outcomes

  1. Change from baseline in MADRS total score at each other than Day 14 timepoint

    The MADRS is a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The test consists of 10 items, each scored from 0 (symptoms not present or normal) to 6 (severe or continuous presence of the symptoms). Total score is 60. The higher MADRS total score, the more severe depression.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12 and week 3, 4, 5, 6, 7 and 8

  2. Number of participants with clinical response (>= 50% decrease in MADRS baseline score)

    Clinical response is to be defined as greater than or equal to 50 % decrease in MADRS baseline score at Day 14 and every other timepoint.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase

  3. Onset of clinical response that was sustained through the end of the 2-week, double-blind, treatment phase

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14

  4. Change from baseline in depression severity, measured by Hamilton Depression Rating Scale (HDRS) at every timepoint

    HDRS is a questionnaire used to rate the severity of depression by probing mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss and somatic symptoms.HDRS consists of 17 questions with maximum 4-points scale. The higher HDRS total score, the more severe depression.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8

  5. Number of participants with clinical remission (MADRS total score <= 10)

    Clinical remission, defined as MADRS total score less than or equal to 10.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and up to 6 weeks after the treatment phase

  6. Time to relapse

    Relapse assessed for responders and remitters and defined when MADRS total score in 2 consecutive assessments after Day 14 exceeds 50% MADRS baseline total score value.

    Time frame: Day 14 and week 3, 4, 5, 6, 7 and 8

  7. Change from baseline in Clinical Global Impression - Severity (CGI-S) score at Day 14 and every other timepoint

    CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1 = normal (not at all ill) and 7 = among the most extremely ill patients.

    Time frame: Day 1, 2, 4, 5, 8, 9, 11, 12, 14 and week 3, 4, 5, 6, 7 and 8

  8. Change from baseline in Columbia Suicide Severity Rating Scale (C-SSRS) at Day 14 and every other timepoint

    C-SSRS is a suicide ideation rating scale created by researchers at Columbia University.

    Time frame: Day 1, 14 and week 5, 8

  9. Change from baseline in the Clinician Administered Dissociative States Scale (CADSS) at each day of administration

    CADSS is a scale designed to assess dissociative symptoms. CADSS consists of 23 questions with 4-points scale, where 1=normal (not at all) and 4=Extremely. The higher CADSS total score, the more severe symptoms.

    Time frame: up to 24 hours following the start of each administration

  10. Change from baseline in the Brief Psychiatric Rating Scale (BPRS) at each day of administration

    BPRS is a scale designed to rate psychotomimetic effects. BPRS consists of 18 questions with 7-points scale, from 1 (not present) to 7 (extremaly severe). The higher BPRS total score, the more severe effects.

    Time frame: up to 24 hours following the start of each administration

  11. Severity of manic behaviour as assessed by the Young Mania Rating Scale (YMRS)

    Young Mania Rating Scale is a scale to rate manic-like mood elevation.YMRS consists of 11 items. The seven items have 4-points scale and four items have 8-points scale. The higher YMRS total score, the more severe manic symptoms.

    Time frame: Day 0, 3, 7, 10, 14 and week 3, 4, 5, 6, 7, 8

  12. Potential withdrawal symptoms after Esketamine treatment, as measured by the 20-item Physician Withdrawal Checklist (PWC-20)

    PWC-20 is a method to assess discontinuation symptoms.

    Time frame: Day 0, week 3, 4 and 5

  13. Potential Esketamine effect on cognition as measured by Montreal Cognitive Assessment (MoCA)

    MoCA is a screening assessment for detecting cognitive impairment.

    Time frame: Day 0, week 4 and 8

  14. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: up to 8 weeks

  15. Esketamine AUC0-24h - area under the plasma concentration - time curve from 0 to 24 h

    Time frame: up to 24 hours following the start of first and fourth administration

  16. Esketamine Cmax - maximum plasma concentration

    Time frame: up to 24 hours following the start of first and fourth administration

  17. Esketamine AUC0-inf - area under the plasma concentration - time curve from 0 to infinity

    Time frame: up to 24 hours following the start of first and fourth administration

  18. Esketamine Kel - terminal elimination rate constant

    Time frame: up to 24 hours following the start of first and fourth administration

  19. Esketamine t1/2 - plasma elimination half-life

    Time frame: up to 24 hours following the start of first and fourth administration

  20. Esketamine Tmax - time to reach maximum concentration in plasma

    Time frame: up to 24 hours following the start of first and fourth administration

  21. Esnorketamine AUC0-24h - area under the plasma concentration - time curve from 0 to 24 h

    Time frame: up to 24 hours following the start of first and fourth administration

  22. Esnorketamine Cmax - maximum plasma concentration

    Time frame: up to 24 hours following the start of first and fourth administration

  23. Esnorketamine Tmax - time to reach maximum concentration in plasma

    Time frame: up to 24 hours following the start of first and fourth administration

  24. Changes between predose and postdose values for each administration in hematology and biochemistry

    Time frame: up to 6 weeks

  25. Changes between predose and postdose values for each administration in vital signs (heart rate, blood pressure, respiratory rate) and urinalysis

    Time frame: up to 8 weeks

  26. Changes between predose and postdose values for each administration in SpO2 (blood oxygen saturation)

    Time frame: up to 2 hours following the start of each administration

07

Study locations

12 sites
  • Wojewodzki Szpital im. Jana Pawła II
    Belchatow, 97-400, Poland
  • Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych
    Boleslawiec, 59-700, Poland
  • Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej
    Choroszcz, 16-070, Poland
  • Szpital Miejski
    Elblag, 82-300, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Gornoslaskie Centrum Medyczne
    Katowice, 40-635, Poland
  • Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej
    Lodz, 91-229, Poland
  • Pabianickie Centrum Medyczne
    Pabianice, 95-200, Poland
  • Mazowieckie Specjalistyczne Centrum Zdrowia
    Pruszkow, 05-802, Poland
  • Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych
    Swiecie, 86-100, Poland
  • Mazowiecki Szpital i Centrum Diagnostyczne Allenort
    Warsaw, 03-185, Poland
  • Uniwersytecki Szpital Kliniczny
    Wroclaw, 50-556, Poland
08

References and documents

Publications

  • Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PubMed 34510411 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jan 2021, 21 months.

Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
May 29, 2019
StartActual
Mar 28, 2019
Primary completionActual
Jan 3, 2021
CompletionActual
Feb 19, 2021
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03965871
Lead sponsor
Celon Pharma SA
Collaborators
National Center for Research and Development, Poland
Responsible party
Sponsor
First posted
May 29, 2019
Start date
Mar 28, 2019
Primary completion
Jan 3, 2021
Completion
Feb 19, 2021
Last update
Mar 19, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion